{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:23:54Z","timestamp":1793931834057,"version":"4.8.0"},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Mogamulizumab was compared with vorinostat in the phase 3 MAVORIC trial (NCT01728805) in 372 patients with relapsed\/refractory mycosis fungoides (MF) or S\u00e9zary syndrome (SS) who had failed \u22651 prior systemic therapy. Mogamulizumab significantly prolonged progression\u2010free survival (PFS), with a superior objective response rate (ORR) vs. vorinostat.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This post hoc analysis was performed to evaluate the effect of baseline blood tumour burden on patient response to mogamulizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PFS, ORR, time to next treatment (TTNT), skin response (modified Severity\u2010Weighted Assessment Tool [mSWAT]) and safety were assessed in patients stratified by blood classification (B0 [<jats:italic>n<\/jats:italic>\u00a0=\u00a0126], B1 [<jats:italic>n<\/jats:italic>\u00a0=\u00a062], or B2 [<jats:italic>n<\/jats:italic>\u00a0=\u00a0184], indicating increasing blood involvement).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Investigator\u2010assessed PFS was longer for mogamulizumab versus vorinostat across all blood classes, significantly so for B1 and B2 patients. ORR was higher with mogamulizumab than with vorinostat in all blood classification groups and more markedly so with escalating B class (B0: 15.6% vs. 6.5%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0549; B1: 25.8% vs. 6.5%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.2758; B2: 37.4% vs. 3.2%, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001). TTNT was significantly longer for patients treated with mogamulizumab versus vorinostat with B1 (12.63 vs. 3.07\u00a0months; HR 0.32 [95% CI 0.16\u20130.67]; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0018) and B2 (13.07 vs. 3.53\u00a0months; HR 0.30 [95% CI 0.21\u20130.43]; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001) blood involvement. In the mogamulizumab arm, 81 patients (43.5%) had \u226550% change in the mSWAT vs. 41 patients (22.0%) with vorinostat; mSWAT improvements with mogamulizumab occurred most often in B1 and B2 patients. Rapid, sustained reductions were seen in CD4<jats:sup>+<\/jats:sup>CD26<jats:sup>\u2010<\/jats:sup> cell counts and CD4:CD8 ratios in mogamulizumab patients for all B classes. Treatment\u2010emergent adverse events were less frequent overall with mogamulizumab and similar in frequency regardless of B class.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This post hoc analysis indicates greater clinical benefit with mogamulizumab vs. vorinostat in patients with MF and SS classified as having B1 and B2 blood involvement.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.17523","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T17:35:40Z","timestamp":1626543340000},"page":"2225-2238","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9004-8136","authenticated-orcid":false,"given":"R.A.","family":"Cowan","sequence":"first","affiliation":[{"name":"Christie Hospital Foundation NHS Trust University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Scarisbrick","sequence":"additional","affiliation":[{"name":"University Hospital Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Zinzani","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italia"},{"name":"Istituto di Ematologia \u2018Ser\u00e0gnoli\u2019 Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit\u00e0 degli Studi Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Nicolay","sequence":"additional","affiliation":[{"name":"University Medical Centre Mannheim Mannheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sokol","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pinter\u2010Brown","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center University of California\u2010Irvine Orange CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-9586","authenticated-orcid":false,"given":"P.","family":"Quaglino","sequence":"additional","affiliation":[{"name":"University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Iversen","sequence":"additional","affiliation":[{"name":"Department of Dermatology Aarhus University Hospital Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"R.","family":"Dummer","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts Spital Z\u00fcrich Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Musiek","sequence":"additional","affiliation":[{"name":"Division of Dermatology Washington University in Saint Louis St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Foss","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation Yale School of Medicine New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ito","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Pharmaceutical Development, Inc. Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u2010P.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Kyowa Kirin International Buckinghamshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Medley","sequence":"additional","affiliation":[{"name":"Kyowa Kirin International Buckinghamshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.7.854"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184168"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.7665"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.01.076"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.3.624"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22252"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16021"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17240"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S165615"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.19610.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1505"},{"key":"e_1_2_7_15_1","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T\u2010cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida T","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3207"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.95_2630"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082311"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-588236"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0830"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17523","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.17523","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T14:22:39Z","timestamp":1692454959000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.17523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1111\/jdv.17523"],"URL":"https:\/\/doi.org\/10.1111\/jdv.17523","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"2021-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}